Regional CAR T cell therapy: An ignition key for systemic immunity in solid tumors

Cancer Cell. 2022 Jun 13;40(6):569-574. doi: 10.1016/j.ccell.2022.04.006. Epub 2022 Apr 28.

Abstract

The success of chimeric antigen receptor (CAR) T cell therapy in solid tumors, unlike in hematologic malignancies, is limited by inadequate tumor infiltration and T cell dysfunction and exhaustion. Regional delivery of CAR T cells in patients with solid tumors is safe and feasible; promotes infiltration, proliferation, and trafficking; and ignites functionally persisting systemic immunity.

Keywords: adoptive cell therapy; chimeric antigen receptor (CAR) T cells; regional therapies; solid tumors cell therapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, N.I.H., Extramural

MeSH terms

  • Antigens, Neoplasm
  • Humans
  • Immunotherapy, Adoptive
  • Neoplasms* / therapy
  • Receptors, Antigen, T-Cell / genetics
  • Receptors, Chimeric Antigen*
  • T-Lymphocytes
  • Tumor Microenvironment

Substances

  • Antigens, Neoplasm
  • Receptors, Antigen, T-Cell
  • Receptors, Chimeric Antigen